CM
BBIO icon

Caption Management’s BridgeBio Pharma BBIO Stock Holding History

Caption Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.46M Sell
60,000
-140,000
-70% -$10.1M 0.03% 563
2025
Q4 		$15.3M Buy
200,000
+50,000
+33% +$3.28M 0.1% 232
2025
Q3 		$7.79M Buy
150,000
+80,000
+114% +$3.9M 0.06% 352
2025
Q2 		$3.02M Sell
70,000
-226,500
-76% -$8.24M 0.03% 582
2025
Q1 		$10.3M Buy
296,500
+186,500
+170% +$6.29M 0.1% 201
2024
Q4 		$3.02M Sell
110,000
-180,100
-62% -$4.65M 0.03% 550
2024
Q3 		$7.39M Sell
290,100
-598,400
-67% -$15.7M 0.12% 206
2024
Q2 		$22.5M Buy
888,500
+383,200
+76% +$10.5M 0.35% 60
2024
Q1 		$15.6M Buy
505,300
+475,300
+1,584% +$16.2M 0.24% 105
2023
Q4 		$1.21M Buy
30,000
+200
+0.7% +$6.01K 0.02% 761
2023
Q3 		$786K Sell
29,800
-705,900
-96% -$20M 0.01% 834
2023
Q2 		$12.7M Buy
735,700
+590,700
+407% +$8.89M 0.22% 111
2023
Q1 		$2.4M Buy
+145,000
New +$1.69M 0.05% 401
2022
Q4 		– Sell
-57,500
Closed -$573K – 1288
2022
Q3 		$573K Sell
57,500
-5,000
-8% -$51.9K 0.01% 1038
2022
Q2 		$568K Buy
62,500
+12,500
+25% +$105K 0.01% 1045
2022
Q1 		$507K Sell
50,000
-795,800
-94% -$8.17M 0.01% 1140
2021
Q4 		$14.1M Buy
+845,800
New +$35.8M 0.16% 164
2020
Q4 		– Sell
-12,500
Closed -$469K – 969
2020
Q3 		$469K Buy
+12,500
New +$393K 0.01% 783

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's BBIO Position: Q1 2026 in Review

Caption Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 431 shares worth $32K. The stake represents ﹤0.01% of the portfolio and ranks #1440 among its holdings. This is a return to the name: Caption Management previously reported a position in BBIO as recently as Q4 2024.

Caption Management first reported a position in BBIO in Q4 2021 and has held it in 9 quarters since. The position peaked at $10.3M in Q2 2024. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Caption Management held 431 shares of BridgeBio Pharma worth $32K as of Q1 2026.
  • BridgeBio Pharma was a new Caption Management position in Q1 2026.
  • BridgeBio Pharma made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1440 holding.
  • Caption Management first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 9 quarters since.
  • Caption Management's BridgeBio Pharma position peaked at $10.3M in Q2 2024.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.